Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery.

Pfeiffer N, Voykov B, Renieri G, Bell K, Richter P, Weigel M, Thieme H, Wilhelm B, Lorenz K, Feindor M, Wosikowski K, Janicot M, Päckert D, Römmich R, Mala C, Fettes P, Leo E.

PLoS One. 2017 Nov 30;12(11):e0188899. doi: 10.1371/journal.pone.0188899. eCollection 2017.

2.

A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours.

Jamieson D, Griffin MJ, Sludden J, Drew Y, Cresti N, Swales K, Merriman M, Allen R, Bevan P, Buerkle M, Mala C, Coyle V, Rodgers L, Dean E, Greystoke A, Banerji U, Wilson RH, Evans TR, Anthoney A, Ranson M, Boddy AV, Plummer R.

Eur J Cancer. 2016 Nov;68:1-10. doi: 10.1016/j.ejca.2016.08.026. Epub 2016 Sep 28.

PMID:
27693888
3.
4.

Epidemiology of animal bites and rabies cases in India. A multicentric study.

Ichhpujani RL, Mala C, Veena M, Singh J, Bhardwaj M, Bhattacharya D, Pattanaik SK, Balakrishnan N, Reddy AK, Samnpath G, Gandhi N, Nagar SS, Shiv L.

J Commun Dis. 2008 Mar;40(1):27-36.

PMID:
19127666
5.

Humoral response to rabies vaccines in pet dogs.

Singh VK, Tiwari KN, Mohan B, Mala C, Rana UV, Ichhpujani RL.

J Commun Dis. 2007 Jun;39(2):109-11.

PMID:
18338690
6.

The Oral Serine Protease Inhibitor WX-671 - First Experience in Patients with Advanced Head and Neck Carcinoma.

Meyer JE, Brocks C, Graefe H, Mala C, Thäns N, Bürgle M, Rempel A, Rotter N, Wollenberg B, Lang S.

Breast Care (Basel). 2008;3(s2):20-24. Epub 2008 Oct 16. No abstract available.

7.

The Role of uPA and uPA Inhibitors in Breast Cancer.

Bevan P, Mala C.

Breast Care (Basel). 2008;3(s2):1-2. Epub 2008 Oct 15. No abstract available.

8.

A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma.

Bleumer I, Oosterwijk E, Oosterwijk-Wakka JC, Völler MC, Melchior S, Warnaar SO, Mala C, Beck J, Mulders PF.

J Urol. 2006 Jan;175(1):57-62.

PMID:
16406869
9.

Radioimmunotherapy with [131I]cG250 in patients with metastasized renal cell cancer: dosimetric analysis and immunologic response.

Brouwers AH, Buijs WC, Mulders PF, de Mulder PH, van den Broek WJ, Mala C, Oosterwijk E, Boerman OC, Corstens FH, Oyen WJ.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7178s-7186s.

10.

Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131I-cG250 in patients with metastasized clear cell renal cell carcinoma.

Brouwers AH, Mulders PF, de Mulder PH, van den Broek WJ, Buijs WC, Mala C, Joosten FB, Oosterwijk E, Boerman OC, Corstens FH, Oyen WJ.

J Clin Oncol. 2005 Sep 20;23(27):6540-8.

PMID:
16170161
11.

Efficacy of low-dose dexamethasone for preventing postoperative nausea and vomiting following strabismus repair in children.

Mathew PJ, Madan R, Subramaniam R, Bhatia A, Mala CG, Soodan A, Kaul HL.

Anaesth Intensive Care. 2004 Jun;32(3):372-6.

12.

A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients.

Bleumer I, Knuth A, Oosterwijk E, Hofmann R, Varga Z, Lamers C, Kruit W, Melchior S, Mala C, Ullrich S, De Mulder P, Mulders PF, Beck J.

Br J Cancer. 2004 Mar 8;90(5):985-90.

13.

Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with (131)I or (111)In: an intrapatient comparison.

Brouwers AH, Buijs WC, Oosterwijk E, Boerman OC, Mala C, De Mulder PH, Corstens FH, Mulders PF, Oyen WJ.

Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3953S-60S.

14.

A prospective open-label single-arm phase II study of chimeric monoclonal antibody cG250 in advanced renal cell carcinoma patients.

Varga Z, de Mulder P, Kruit W, Hegele A, Hofmann R, Lamers C, Warnaar S, Mala C, Ullrich S, Mulders P.

Folia Biol (Praha). 2003;49(2):74-7.

PMID:
12779016
15.

Spinalin, a new glycine- and histidine-rich protein in spines of Hydra nematocysts.

Koch AW, Holstein TW, Mala C, Kurz E, Engel J, David CN.

J Cell Sci. 1998 Jun;111 ( Pt 11):1545-54.

Supplemental Content

Support Center